ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head Trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis
December 25, 2019MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology based topical therapies for chronic inflammatory conditionss, announced that its EU Phase 3 trial (n=490) on the company’s investigational drug ... -
MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis
November 26, 2019MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions ... -
MC2 Therapeutics reports positive Phase III results for experimental psoriasis cream
August 22, 2018MC2 Therapeutics on Tuesday announced that its investigational psoriasis cream MC2-01 (calcipotriene/betamethasone) demonstrated "significant superiority" in a Phase III trial in terms of both treatment...... -
MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris
October 13, 2017MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that first patient has been dosed in its pivotal Phase 3 clinical trial assessing the safety and efficacy of MC2-01 Cream (calcipotriene and betamethasone
Pharma Sources Insight January 2025
